Geniculate Artery Embolization for the Treatment of Knee Osteoarthritis
Trial Summary
What is the purpose of this trial?
Osteoarthritis (OA) is a highly prevalent degenerative joint disease that contributes to chronic pain and disability in approximately 10% of people over the age of 55. With 25% of Canadians expected to be aged 55 or older by 2036, an increasing number of Canadians will be impacted by knee OA. In affected individuals the risk of medical co-morbidities is increased which can lead to adverse cardiovascular outcomes, depression, and poorer quality of life. Current conservative therapy includes oral analgesia, lifestyle modification, corticosteroid injection, and viscosupplementation. These current conservative measures have variable responses. In patients who would prefer to avoid surgery or are not surgical candidates safe and consistently effective treatment options are lacking. Geniculate artery embolization (GAE) is a minimally invasive alternative with low risk of complications that has shown promise in exploratory studies. GAE provides benefit by disrupting angiogenesis in the knee which can contribute to chronic inflammation of the affected joint, and helps prevent the growth of new sensory nerve fibers which can reduce the pain associated with osteoarthritis.
Research Team
Eligibility Criteria
This trial is for individuals over 40 with knee osteoarthritis who haven't found relief from pain after at least 3 months of conservative treatments, such as medication or injections. It's aimed at those who are not candidates for surgery or choose not to undergo it.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Geniculate Artery Embolization (Procedure)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Calgary
Lead Sponsor